This study is testing a new drug called MRTX1719. The main goal is to find the best dose of the drug to use in future studies. The study will also look at what side effects the drug may cause and how often they happen. Researchers will also measure how quickly the drug is absorbed into the bloodstream and how fast the body gets rid of it. Additionally, they will check how well MRTX1719 works against cancer.

The purpose of this study is to see if adding LY3537982 to standard cancer treatments works better than just using the standard treatments alone for people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated.

Do you have a solid tumor that has progressed on other treatments? Do you have at least one measurable tumor? If so, you may be able to take part in a study to improve treatment for advanced solid tumors. We are exploring how safe and effective a combination of drugs is.

In this study, researchers want to find out the highest safe dose of a drug called [212Pb]VMT-α-NET that can be used to treat neuroendocrine tumors.

Have you been diagnosed with Severe Aplastic Anemia (SAA), but don't have a matched sibling donor? If so, you may be able to take part in a study to see if a bone marrow transplant from a donor that is not related can help treat your disease. Compensation provided.

Have you been diagnosed with cancer? If so, you may have the opportunity to participate in a research study designed to examine how central oncology navigation affects the use of supportive care services. Additionally, the study will assess whether enrollment in non-treatment clinical trials increases with the implementation of an Oncology Navigation Resource (ORN) intervention.

In this study, we want to see how well a new drug called Quizartinib works for people with Leukemia who do not have a specific mutation called FLT3-ITD. We want to see if this new drug helps improve the condition.

The purpose of this study is to find out how safe and effective a new CAR-T study treatment, called MB-105, is for people with T-cell lymphoma. MB-105 is an experimental study treatment. This means it is not approved for general use by the U.S. Food and Drug Administration (FDA) and, as such, can only be used in research studies.

In this study, we want to see if a new drug called petosemtamab is effective. The study is for patients who have head and neck cancer that has spread or come back and cannot be cured. We want to see if petosemtamab works better than the treatments doctors usually use.

Have you had an organ transplant or hematopoietic cell transplant and have advanced cutaneous squamous cell carcinoma? If so, you might be eligible to take part in a study to see if an investigation drug, RP1, can help treat your skin cancer.